BioCentury | Oct 7, 2020
Deals

Roche deal for CF program brings return to Enterprise’s syndicate without full takeout

...CFTR have transformed the CF treatment landscape in recent years. Those, including Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor...
BioCentury | Jun 30, 2020
Product Development

Vertex, NHS in deal to make CF triplet available in England once EC approves

...struck last October between Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) and NHS that had provided access to Orkambi...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...and the cystic fibrosis franchise from Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), which includes Kalydeco ivacaftor, Orkambi ivacaftor/lumacaftor...
BioCentury | Nov 1, 2019
Product Development

Vertex’s triple therapy will reshape the landscape of cystic fibrosis trials

...$500M” ). Until now, Vertex’s therapies addressed only half of the CF population, and while Orkambi...
...have been far superior to any other clinical readouts, including those of Vertex’s doublet therapies Orkambi...
...patients with homozygous ΔF508 mutations--each after only four weeks of treatment. Those results easily bested Orkambi...
BioCentury | Oct 24, 2019
Company News

Vertex, NHS England reach agreement on access to CF drugs

...Nearly four years after the European approval of Vertex’s first cystic fibrosis combo therapy Orkambi, the...
...addition to Orkambi for CF patients aged 2-5 with two copies of the ΔF508 mutation. Orkambi...
...disclosed. Vertex rose $3.96 to $194.47 Thursday. Stephen Hansen, Associate Editor Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi...
BioCentury | Sep 24, 2019
Politics & Policy

Labour leader Corbyn vows compulsory licensing to slash prices of patented drugs

...said he had recently met with a cystic fibrosis patient who could benefit from Orkambi ivacaftor/lumacaftor...
...price.” Vertex has reached an agreement with Scotland on a discounted price for CF drugs Orkambi...
...At a parliamentary debate in June, several MPs spoke in favor of compulsory licensing of Orkambi...
BioCentury | Sep 13, 2019
Company News

Vertex reaches CF deal in Scotland

...Thursday that it reached a deal with the Scottish government to provide access to Orkambi ivacaftor/lumacaftor...
...available on the NHS. Meanwhile, NHS England and Vertex have been negotiating the price of Orkambi...
...same access agreement in place” as Scotland’s. Inhua Muijrers-Chen, Associate Editor Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi...
BioCentury | Aug 22, 2019
Politics & Policy

Changing of the guard at NICE

...some high-priced Orphan drugs to navigate. In the case of cystic fibrosis, access to Orkambi ivacaftor/lumacaftor...
BioCentury | Aug 12, 2019
Company News

Vertex fails to reach CF deal in Scotland

...Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) had agreed to an interim deal in December to make Orkambi ivacaftor/lumacaftor...
...in England, where patients have been fighting for over three years to gain access to Orkambi...
...Compulsory Licensing of CF Drugs" ). Elizabeth S. Eaton, Staff Writer Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi...
BioCentury | Jul 25, 2019
Company News

As Vertex broadens remit, Leiden handing baton to Kewalramani

...Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) through the launches of its three CF drugs: Symdeko tezacaftor/ivacaftor, Orkambi ivacaftor/lumacaftor...
...U.K., where the company and government agencies are locked in a stalemate over access to Orkambi...
...$3.78 to $169.56 Thursday. Elizabeth S. Eaton, Staff Writer Kalydeco, ivacaftor (VX-770) Orkambi (Brand), ivacaftor/VX-809 (Generic), ivacaftor/lumacaftor (Generic), Orkambi...
Items per page:
1 - 10 of 147